One-year trajectories of physical and mental health-related quality of life, fatigue and dyspnoea in COVID-19 survivors.

Publication date: Oct 19, 2024

A substantial number of people experience a persisting impact on health-related quality of life (HRQoL) after COVID-19. The current study aims to identify different trajectories of physical and mental HRQoL, fatigue severity, and dyspnoea severity following hospitalisation with COVID-19, and associated factors of these trajectories. 500 patients with COVID-19 were followed for one year in a longitudinal cohort study. Self-reported outcomes were measured at 3, 6, 9, and 12 months after hospitalisation. Distinct trajectories were characterised using Growth Mixture Modelling. Sociodemographic and clinical correlates of trajectories were investigated using multivariable (multinomial) logistic regression analyses. Three trajectories (‘stable high’ (16%), ‘improving’ (40%), and ‘stable low’ (44%)) were found for physical HRQoL, and four (‘stable high’ (43%), ‘improving’ (14%), ‘middle declining’ (17%), and ‘low’ (26%)) for mental HRQoL. Older age, overweight and obesity, lower education, and comorbidities were associated with ‘low’ physical HRQoL. Younger age was associated with ‘low’ mental HRQoL. Four fatigue trajectories (‘no fatigue’ (15%), ‘improving’ (40%), ‘low-severe’ (27%), and ‘high-severe’ (18%)) were found. Participants either experienced almost never (‘no dyspnoea’, 75%) or almost always (‘severe’, 25%) dyspnoea. High co-occurrences between low HRQoL and severe fatigue and dyspnoea symptom trajectories were found. A substantial number of COVID-19 survivors continue to struggle with reduced HRQoL over time. However, large variations in these physical and mental HRQoL trajectories exist, and trajectories are associated with persisting COVID-19-related symptoms or pre-hospitalised health status. Regular measurement of HRQoL and post-COVID symptoms may help identify those that may benefit from timely interventions.

Open Access PDF

Concepts Keywords
Hospitalised COVID-19
Obesity Dyspnoea
Sociodemographic Fatigue
Post-COVID-19 syndrome
Quality of life

Semantics

Type Source Name
disease IDO quality
disease MESH COVID-19
disease MESH overweight
disease MESH obesity
disease IDO symptom
disease MESH health status
disease MESH syndrome
disease MESH Long COVID
drug DRUGBANK Pentaerythritol tetranitrate
disease MESH cognitive dysfunction
disease MESH brain fog
disease MESH anxiety
disease MESH sequelae
disease IDO intervention
disease MESH cancer
disease MESH depression
drug DRUGBANK Coenzyme M
disease MESH comorbidity
disease IDO blood
disease MESH skin diseases
disease MESH chronic conditions
disease MESH chronic fatigue syndrome
disease MESH tics
drug DRUGBANK Trestolone
drug DRUGBANK Indoleacetic acid
disease MESH inflammation
disease MESH necrosis
disease MESH psychiatric disorders
disease MESH post traumatic stress disorder
disease MESH uncertainty
disease MESH pulmonary fibrosis
disease IDO process
disease IDO acute infection
disease MESH urinary tract infection
disease MESH lung cancer
drug DRUGBANK Methylergometrine
disease MESH infection
disease MESH Infectious Diseases
disease MESH chronic pain
drug DRUGBANK Guanosine
disease MESH Affective Disorders
pathway REACTOME Reproduction
drug DRUGBANK (S)-Des-Me-Ampa
disease MESH Return to work
drug DRUGBANK Silver
drug DRUGBANK Elm
pathway REACTOME Translation
disease MESH Dyspnea
drug DRUGBANK Gold
drug DRUGBANK L-Aspartic Acid
disease MESH rheumatoid arthritis
pathway KEGG Rheumatoid arthritis

Original Article

(Visited 3 times, 1 visits today)